Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review

Renaissance of the Blocking Antibody Concept in Type I Allergy

Flicker S. · Valenta R.

Author affiliations

Division of Immunopathology, Department of Pathophysiology, University of Vienna, Vienna General Hospital, Vienna, Austria

Related Articles for ""

Int Arch Allergy Immunol 2003;132:13–24

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: October 17, 2003
Issue release date: September 2003

Number of Print Pages: 12
Number of Figures: 6
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Formation of IgE antibodies against per se harmless antigens (i.e. allergens) is the hallmark and key pathomechanism of type I allergy, a hypersensitivity disease affecting more than 25% of the population. Classical experiments performed more than 65 years ago demonstrated that allergen-specific IgG antibodies, termed blocking antibodies, can antagonize the cascade of allergic inflammation resulting from allergen recognition by IgE antibodies. However, controversial results have questioned the protective role of IgG antibodies in allergic diseases. Here, we review recent data demonstrating that blocking antibodies inhibit allergen-induced release of inflammatory mediators from basophils and mast cells as well as IgE-facilitated allergen presentation to T cells, thus leading to suppression of T cell activation. Furthermore, it has been reported that the development of blocking antibodies is associated with reduced boosts of allergen-specific IgE production in patients receiving allergen-specific immunotherapy. These findings suggest that blocking antibodies have protective activity by inhibiting immediate as well as late inflammatory responses and long-term ameliorating activity on the allergic immune response by antagonizing the underlying IgE production. Induction of blocking antibodies is thus an important mechanism underlying allergen-specific immunotherapy. In addition, passive administration of blocking antibodies may be considered as a potential therapeutic strategy for allergic diseases.

© 2003 S. Karger AG, Basel


References

  1. Kay AB: Allergy and Allergic Diseases. Oxford, Blackwell Science, 1997.
  2. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446–453.
  3. Turner H, Kinet JP: Signalling through the high-affinity IgE receptor epsilonRI. Nature 1999;402:B24–B30.
    External Resources
  4. Kinet JP: The high-affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Annu Rev Immunol 1999;17:931–972.
  5. Nadler MJ, Matthews SA, Turner H, Kinet JP: Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: Coupling form to function. Adv Immunol 2000;76:325–355.
  6. Mudde GC, Hansel TT, von Reijsen FC, Osterhoff BF, Bruinzeel-Koomen CA: IgE: An immunoglobulin specialized in allergen capture? Immunol Today 1990;11:440–443.
  7. Stingl G, Maurer D: IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 1997;113:24–29.
  8. Bieber T: Fc epsilon RI on human epidermal Langerhans cells: An old receptor with new structure and function. Int Arch Allergy Immunol 1997;113:30–34.
  9. VanNeerven RJJ, Wikbog T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944–2952.
  10. Prausnitz C, Küstner H: Studien über die Überempfindlichkeit. Centralbl Bakteriol 1921;86:160–169.
  11. Coca AF, Grove EF: Studies in hypersensitiveness. XII. A study of the atopic reagins. J Immunol 1925;10:445–464.
  12. Ishizaka K, Ishizaka T: Identification of gamma-E antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187–1198.
  13. Johansson SGO, Bennich H, Wide L: A new class of immunoglobulin in human serum. Immunology 1968;14:265–272.
  14. Bennich H, Ishizaka K, Johansson SGO, et al: Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968;38:151–152.
  15. Wide L, Bennich H, Johansson SGO: Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet 1967;ii:1105–1107.
  16. Cooke RA, Bernhard JH, Hebald S, Stull A: Serological evidence of immunity with co-existing sensitization in hay fever type of human allergy. J Exp Med 1935;62:733–750.
    External Resources
  17. Loveless MH: Immunological studies of pollinosis. I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J Immunol 1940;38:25–50.
  18. Loveless MH: Immunological studies of pollinosis. IV. The relationship between thermostable antibody in the circulation and clinical immunity. J Immunol 1943;47:165–180.
  19. Freund J, McDermott K: Sensitization to horse serum by means of adjuvants. Proc Soc Exp Biol Med 1942;49:548–553.
  20. Potter M, Boyce ER: Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 1962;193:1086–1087.
  21. Sledge RF: Treatment of hayfever with alum-precipitated pollen. US Nav Med Bull 1938;36:18–19.
  22. Petillo J, Smith SR: Reaginic response in rats to alum precipitated antigens. I. Time course of appearance of anti-egg albumin reagins and potentiation of the response with Nippostronglus brasiliensis. Int Arch Allergy Appl Immunol 1973;44:309–320.
  23. Norman PS, Lichtenstein LM: Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1978;61:384–389.
  24. Nelson HS: Long-term immunotherapy with aqueous and aluminium-precipitated grass extracts. Ann Allergy 1980;45:333–337.
  25. Bousquet J, Lockey R, Malling HJ, and the WHO panel members: Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558–562.
  26. Lichtenstein LM, Holtzman NA, Burnett LS: A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:317–324.
  27. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM: IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472–482.
  28. Tada T, Okumura K: Regulation of homocytotropic antibody formation in the rat. I. Feed-back regulation by passively administered antibody. J Immunol 1971;106:1002–1011.
  29. Sobotka AK, Valentine MD, Ishizaka K, Lichtenstein LM: Measurement of IgG-blocking antibodies: Development and application of a radioimmunoassay. J Immunol 1976;117:84–90.
  30. Adkinson NF, Sobotka AK, Lichtenstein LM: Evaluation of the quantity and affinity of human IgG ‘blocking’ antibodies. J Immunol 1979;122:965–972.
  31. Gleich GJ, Zimmermann EM, Gleich MC, Yuninger JW: Measurement of IgG blocking antibodies by interference in the radioallergosorbent test. J Immunol 1981;126:575–579.
  32. Gleich GJ, Zimmermann EM, Henderson LL, Yuninger JW: Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: A six-year prospective study. J Allergy Clin Immunol 1982;70:261–271.
  33. Aalberse RC, Gaag R, Leeuwen J: Serological aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130:722–726.
  34. Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, Leeuwen JV: IgG4 as blocking antibody. Clin Rev Allergy 1983;1:289–302.
  35. Djurup R, Osterballe O: IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984;39:433–441.
  36. Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ: Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgG1 with clinical response. J Allergy Clin Immunol 1987;79:387–398.
  37. Gelhar K, Schlaak M, Becker W, Bufe A: Monitoring allergen immunotherapy of pollen-allergic patients: The ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999;29:497–506.
  38. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valent R: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:2026–2036.
  39. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, Valenta R: B cell epitopes of the major timothy grass pollen allergen Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999;13:1277–1290.
  40. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R: Immunotherapy with a tyrosine-absorbed, monophosphoryl lipid A-adjuvanted grass pollen allergoid: Reduced seasonally boosted IgE production and inhibition of basophil histamine release by therapy-induced IgG antibodies. Clin Exp Allergy 2003;33:1–11.
  41. Djurup R, Malling HJ: High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459–468.
  42. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CDR and CRIT). Clin Exp Allergy 1999;29:896–904.
  43. Visco V, Dolecek C, Denepoux S, LeMao J, Guret C, Rousset F, Guinnepain MT, Kraft D, Valenta R, Weyer A, Bancereau J, Lebecque S: Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157:956–962.
  44. Denepoux S, Eibensteiner P, Steinberger P, Vrtala S, Visco V, Weyer D, Bancherau J, Valenta R, Lebecque S: Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett 2000;465:39–46.
  45. Marsh DG, Lichtenstein LM, Campell DH: Studies on ‘allergoids’ prepared from naturally occurring allergens. Immunology 1970;18:705–722.
  46. Valenta R, Kraft D: From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002;14:718–727.
  47. Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R: Nonanaphylactic synthetic peptides derived from B cell epitopes of the grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001;15:2042–2044.
  48. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of a hypoallergenic trimer of the major birch-pollen allergen Bet v 1. FASEB J 2001;15:2045–2047.
  49. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R: Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002;16:1301–1303.
  50. Reese G, Becker WM, Schlaak M: Farmer’s lung: IgG-subclass reactivities against thermophilic actinomycetes (in German). Immun Infekt 1989;17:59–60.
  51. Fagarasan S, Honjo T: Intestinal IgA synthesis: Regulation of front-line body defences. Nat Rev Immunol 2003;3:63–72.
  52. Bracke M, van de Graaf E, Lammers JW, Coffer PJ, Koenderman L: In vivo priming of FcalphaR functioning on eosinophils of allergic asthmatics. J Leukoc Biol 2000;68:655–661.
  53. Monteiro RC, Van De Winkel JG: IgA Fc receptors. Annu Rev Immunol 2003;21:177–204.
  54. Sollid LM: Coeliac disease: Dissecting a complex inflammatory disorder. Nat Rev Immunol 2002;2:647–655.
  55. Hoffmann-Sommergruber K, Ferreira F, Ebner C, Barisani T, Korninger L, Kraft D, Scheiner O, Baumgartner I: Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. Clin Exp Allergy 1996;26:79–87.
  56. Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R: Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: A study performed with purified recombinant pollen allergens. J Allergy Clin Immunol 2000;105:803–813.
  57. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol 2001;19:275–290.
  58. Ishizaka T, Sterk AR, Ishizaka K: Demonstration of Fcγ receptors on human basophil granulocytes. J Immunol 1979;123:578–583.
  59. Okayama Y, Kirshenbaum AS, Metcalfe DD: Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: Up-regulation by IFN-γ. J Immunol 2000;164:4332–4339.
  60. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH: The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3:635–646.
  61. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A: A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med 2002;8:518–521.
  62. Okayama Y, Hagaman DD, Woolhiser M, Metcalfe DD: Further characterization of FcγRII and FcγRIII expression by cultured human mast cells. Int Arch Allergy Immunol 2001;124:155–157.
  63. Platts-Mills TA, von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM: IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976;57:1041–1050.
  64. Jerne NK: Towards a network of the immune system. Ann Immunol 1974;125:373–389.
  65. Bose R, Marsh DG, Delespesse G: Anti-idiotypes to anti-Lol p I (Rye) antibodies in allergic and non-allergic individuals. Influence of immunotherapy. Clin Exp Immunol 1986;66:231–240.
  66. Saint-Remy JM, Lebecque SJ, Lebrun PM, Jacquemin MG: Human immune response to allergens of house-dust mite, Dermatophagoides pteronyssinus. 4. Occurrence of natural autologous anti-idiotypic antibodies. Eur J Immunol 1988;18:83–87.
  67. Hebert J, Bernier D, Mourad W: Detection of auto-anti-idiotypic antibodies to Lol p I (Rye I) IgE antibodies in human sera by the use of murine idiotypes: Levels in atopic and non-atopic subjects and effects on immunotherapy. Clin Exp Immunol 1990;80:413–419.
  68. Valacer DJ, O‘Reilly ME, Ilowite NT, Bonagura VR: Identification of anti-idiotypic antibodies in the sera of ryegrass-allergic and nonallergic individuals. J Allergy Clin Immunol 1991;88:349–355.
  69. Weyer A, Le Mao J, Etievant M, David B, Guinnepain T, Saint-Remy JMR: Human auto-anti-idiotypic antibodies to mite-specific IgE can regulate human basophils in vitro. Clin Exp Allergy 1995;25:935–941.
  70. Clinton PM, Kemeny DM, Youlten LJ, Lessof MH: Histamine release from peripheral blood leukocytes with purified bee venom allergens: Effect of hyperimmune beekeeper plasma. Int Arch Allergy Immunol 1989;89:43–48.
  71. Wachholz PA, Kristensen Soni N, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies following grass pollen immunotherapy. J Allergy Clin Immunol, in press.
  72. Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B, Sperr WR, Valent P, Kraft D, Valenta R: Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998;160:6137–6144.
  73. Steinberger P, Kraft D, Valenta R: Construction of a combinatorial library from an allergic patient. J Biol Chem 1996;271:10967–10972.
  74. Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R: Conversion of grass pollen allergen-specific human IgE into a protective IgG1 antibody. Eur J Immunol 2002;32:2156–2162.
  75. Valenta R, Flicker S, Eibensteiner P, Steinberger P, Laffer S, Dolecek C, Kraft D: Recombinant allergen-specific antibody fragments: Tools for diagnosis, prevention and therapy of type I allergy. Biol Chem 1997;378:745–749.
  76. Lanzavecchia A: Antigen-specific interaction between T and B cells. Nature 1985;314:537–539.
  77. Lanzavecchia A: Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev 1987;99:39–51.
  78. Durham SR, Till SJ: Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157–164.
  79. Henderson LL, Larson JB, Gleich GJ: Maximal rise in IgE antibody following ragweed pollination season. J Allergy Clin Immunol 1975;55:10–15.
  80. Naclerio RM, Adkinson NF Jr, Moylan B, Baroody FM, Proud D, Kagey-Sobotka A, Lichtenstein LM, Hamilton R: Nasal provocation with allergen induces a secondary serum IgE antibody response. J Allergy Clin Immunol 1997;100:505–510.
  81. Behring E, Kitasato S: Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 1890;16:1113–1114.
  82. Behring E: Zur Behandlung diphtherieerkrankter Menschen mit Diphtherieheilserum; in Behring E (ed): Gesammelte Abhandlungen zur aetiologischen Therapie von ansteckenden Krankheiten. Leipzig, Thieme, 1893, pp 311–316.
  83. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497.
  84. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton D, Benkovic SJ, Lerner RA: Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989;246:1275–1281.
  85. Burton DR, Barbas CF: Human antibodies from combinatorial libraries. Adv Immunol 1994;57:191–279.
  86. Valenta R, Kraft D: From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002;14:718–727.
  87. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritschnig K, Kraft D: Immunotherapy of allergic disease. Adv Immunol, in press.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: October 17, 2003
Issue release date: September 2003

Number of Print Pages: 12
Number of Figures: 6
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.